Disc Medicine Completes 183-Patient Phase 3 Enrollment, Holds $730M Cash Runway
Disc Medicine completed enrollment of 183 patients in its Phase 3 APOLLO trial of bitopertin for EPP and expects topline data in Q4 2026. The company held $730.2 million in cash and equivalents at quarter end, funding operations into 2029, while net loss widened to $63.5 million.
1. Clinical Trial Milestones
Completed enrollment of 183 patients in the Phase 3 APOLLO trial of bitopertin for EPP, expanded due to demand, with topline results expected Q4 2026; RALLY-MF Phase 2 data from DISC-0974 will be presented at ASCO covering 61 patients through April 27, 2026.
2. Financial Position
Ended Q1 with $730.2 million in cash, cash equivalents, and marketable securities, providing funding into 2029.
3. Expense Growth and Net Loss
R&D expenses rose to $45.9 million from $27.8 million year-over-year due to pipeline advancement and manufacturing, SG&A increased to $23.6 million driven by commercialization infrastructure, leading to a net loss of $63.5 million.
4. Upcoming Catalysts
Type A FDA meeting planned in Q2 to discuss bitopertin resubmission, with an FDA decision expected mid-2027; multiple Phase 2 and Phase 1b data readouts including DISC-3405 and RALLY-MF toplines are set for Q4 2026.